Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RNA | US
-0.03
-0.20%
Healthcare
Biotechnology
30/06/2024
09/03/2026
14.79
14.59
15.01
14.00
Avidity Biosciences Inc. a biopharmaceutical company engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1 a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences Inc. was incorporated in 2012 and is headquartered in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
385.9%1 month
285.9%3 months
162.4%6 months
134.1%-
-
4.74
0.01
0.01
-5.72
424.10
-
-282.67M
1.75B
1.75B
-
-4.04K
-
-11.70
-28.36
8.43
15.45
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
59.99
Range1M
59.99
Range3M
60.00
Rel. volume
0.19
Price X volume
12.26M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Nanobiotix S.A | NBTX | Biotechnology | 40.13 | 1.91B | 18.06% | n/a | -204.27% |
| IRON | IRON | Biotechnology | 64.23 | 1.91B | 4.99% | n/a | 0.38% |
| AnaptysBio Inc | ANAB | Biotechnology | 59.7 | 1.80B | 7.74% | n/a | 3835.68% |
| BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 8.62 | 1.78B | 1.65% | n/a | -178.85% |
| Tyra Biosciences Inc. Common Stock | TYRA | Biotechnology | 33.75 | 1.78B | -3.68% | n/a | 1.70% |
| Dynegy Inc | DYN | Biotechnology | 17.69 | 1.78B | 19.04% | n/a | 3.32% |
| TNGX | TNGX | Biotechnology | 16.45 | 1.76B | -2.95% | n/a | 15.28% |
| Mesoblast Limited | MESO | Biotechnology | 15.43 | 1.76B | -2.65% | n/a | 24.76% |
| Zymeworks Inc | ZYME | Biotechnology | 24.25 | 1.72B | 0.71% | n/a | 4.94% |
| Novavax Inc | NVAX | Biotechnology | 10.55 | 1.69B | 5.71% | n/a | -54.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.67 | 1.92B | 0.85% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.67 | 351.58M | -6.14% | n/a | 174.23% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.72 | 0.53 | Cheaper |
| Ent. to Revenue | 424.10 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.74 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 162.37 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.75B | 3.66B | Emerging |